Table 3. Relationship between clinical characteristics and progression-free survival in patients treated by gefitinib (n=33).
| Median PFS (months) (95% CI) | P valuea | HR, 95% CI | P valueb | |
|---|---|---|---|---|
| Gender | ||||
| Male (n=21) | 2.5 (1.6-3.397) | >0.05 | 0.835 (0.364-01.917) | >0.05 |
| Female (n=12) | 3.5 (1.237-5.763) | |||
| Smoking status | ||||
| Smoker (n=13) | 1.8 (1.213-2.387) | <0.01 | 3.818 (1.437-10.143) | <0.01 |
| Non-smoker (n=20) | 4.0 (2.904-5.096) | |||
| EGFR gene | ||||
| Mutation (n=16) | 4.0 (3.085-4.915) | <0.01 | 2.377 (1.047-5.395) | <0.05 |
| Wild type (n=17) | 2.0 (1.337-2.663) |
EGFR, epidermal growth factor receptor; PFS, progression-free survival. a, P value represents the difference between the two groups; b, P value for trend by Cox proportional hazard mode.